Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Advanced Drug Delivery Reviews is Scopus-indexed (Q1, CiteScore 39), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Elsevier B.V..
Checked against the index lists dated .
ISSN 0169-409XVerify ISSN ↗1872-8294Verify ISSN ↗
Publisher: Elsevier B.V.
Cost to publish: About US$5,550 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmaceutical Science | 1 / 191 | 99th | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1987–present, best quartile Q1, CiteScore 39.
Advanced Drug Delivery Reviews is Q1 in Pharmaceutical Science (rank 1 of 191), by CiteScore 2025.
Advanced Drug Delivery Reviews is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 39, which places it in quartile Q1 at the 99th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 4.015, quartile Q1, with an H-index of 405.
The publisher lists an article processing charge of about US$5,550 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Advanced Drug Delivery Reviews is published by Elsevier B.V. Its print ISSN is 0169-409X and its online ISSN is 1872-8294.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Advanced Drug Delivery Reviews has an h-index of 434 and a 2-year mean of 15.55 citations per paper (OpenAlex). Its Scopus CiteScore is 39, quartile Q1. On 2-year citations it ranks #1 of 177 Scopus journals in Pharmaceutical Science.
Advanced Drug Delivery Reviews published 147 papers in 2025; its busiest recent year was 2021 with 338. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2026), authors are most often from United States (29.1%), China (10.7%) and Canada (10.2%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 1 retracted paper is recorded (0.2 per 1,000 papers). The Problematic Paper Screener flags 1 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.